Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Astria Therapeutics (NASDAQ:ATXS) has granted stock options to two new employees under its 2022 Inducement Stock Incentive Plan. The company awarded options to purchase 43,650 shares of common stock at an exercise price of $5.40 per share, matching the closing price on April 1, 2025.
The options will vest over a four-year period, with 25% vesting on the first employment anniversary and the remaining shares vesting monthly over the following 36 months, contingent on continued employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement material for new hires.
Astria Therapeutics (NASDAQ:ATXS) ha concesso opzioni su azioni a due nuovi dipendenti nell'ambito del suo Piano di Incentivazione delle Azioni per il 2022. L'azienda ha assegnato opzioni per l'acquisto di 43.650 azioni ordinarie a un prezzo di esercizio di $5,40 per azione, corrispondente al prezzo di chiusura del 1° aprile 2025.
Le opzioni matureranno in un periodo di quattro anni, con il 25% che matura al primo anniversario di assunzione e le azioni rimanenti che maturano mensilmente nei successivi 36 mesi, a condizione di continuare l'impiego. Questi conferimenti sono stati effettuati in conformità con Nasdaq Listing Rule 5635(c)(4) come incentivo materiale per le nuove assunzioni.
Astria Therapeutics (NASDAQ:ATXS) ha otorgado opciones sobre acciones a dos nuevos empleados bajo su Plan de Incentivo de Acciones por Inducción de 2022. La empresa otorgó opciones para comprar 43,650 acciones comunes a un precio de ejercicio de $5.40 por acción, coincidiendo con el precio de cierre del 1 de abril de 2025.
Las opciones se consolidarán durante un período de cuatro años, con el 25% consolidándose en el primer aniversario de empleo y las acciones restantes consolidándose mensualmente durante los siguientes 36 meses, dependiendo de la continuidad del empleo. Estas concesiones se realizaron de acuerdo con Nasdaq Listing Rule 5635(c)(4) como incentivo material para nuevas contrataciones.
Astria Therapeutics (NASDAQ:ATXS)는 2022 유인 주식 인센티브 계획에 따라 두 명의 신입 직원에게 주식 옵션을 부여했습니다. 이 회사는 43,650주의 보통주를 $5.40의 행사 가격으로 구매할 수 있는 옵션을 부여했으며, 이는 2025년 4월 1일의 종가와 일치합니다.
옵션은 4년 기간에 걸쳐 분할되어, 첫 번째 고용 기념일에 25%가 확정되고 나머지 주식은 다음 36개월 동안 매월 확정됩니다. 이는 계속 고용되는 조건에 따라 달라집니다. 이러한 부여는 Nasdaq Listing Rule 5635(c)(4)에 따라 신입 직원에 대한 유인 자료로 이루어졌습니다.
Astria Therapeutics (NASDAQ:ATXS) a accordé des options d'achat d'actions à deux nouveaux employés dans le cadre de son Plan d'Incitation aux Actions 2022. L'entreprise a attribué des options pour acheter 43 650 actions ordinaires à un prix d'exercice de 5,40 $ par action, correspondant au prix de clôture du 1er avril 2025.
Les options seront acquises sur une période de quatre ans, avec 25 % acquises lors du premier anniversaire de l'emploi et les actions restantes acquises mensuellement au cours des 36 mois suivants, sous réserve de la poursuite de l'emploi. Ces attributions ont été effectuées conformément à la règle de cotation Nasdaq 5635(c)(4) en tant que matériel d'incitation pour les nouvelles recrues.
Astria Therapeutics (NASDAQ:ATXS) hat zwei neuen Mitarbeitern im Rahmen seines Anreiz-Aktionsplans 2022 Aktienoptionen gewährt. Das Unternehmen vergab Optionen zum Kauf von 43.650 Aktien zu einem Ausübungspreis von 5,40 $ pro Aktie, was dem Schlusskurs vom 1. April 2025 entspricht.
Die Optionen werden über einen vierjährigen Zeitraum fällig, wobei 25 % am ersten Jahrestag der Anstellung fällig werden und die verbleibenden Aktien in den folgenden 36 Monaten monatlich fällig werden, abhängig von der fortgesetzten Anstellung. Diese Zuwendungen wurden gemäß Nasdaq Listing Rule 5635(c)(4) als Anreizmaterial für neue Einstellungen vorgenommen.
- None.
- None.
The options were granted as an inducement material to two employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is an investigational monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on Instagram @AstriaTx and on Facebook and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250402901964/en/
Astria:
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com
Source: Astria Therapeutics, Inc.
FAQ
How many shares are included in ATXS's latest stock option grant?
What is the exercise price for ATXS's April 2025 stock options?
What is the vesting schedule for ATXS's 2025 inducement stock options?
How many employees received ATXS stock options in the April 2025 grant?
